| abstract |
It is intended to disclose a method of screening a protein which ligand- dependently interacts with PPAR and is highly useful as a tool for screening a drug improving insulin resistance. Using this method, a main effect ligand- dependent PPAR-binding molecule ECHLP, a main effect ligand-selective PPAR.gamma. acting factor FLJ13111 and a side effect ligand-dependent PPAR- binding molecule AOP2 are obtained. It is also intended to disclose a screening system for a drug improving insulin resistance selectively exerting the main effect without causing any side effect which is constructed by using PPAR-interacting ECHLP, PPAR-interacting FLJ13111 and PPAR-interacting AOP2. It is furthermore intended to disclose a process for producing medicinal compositions for improving insulin resistance containing, as the active ingredient, a PPAR main effect promoter, a PPAR main effect-specific agonist, a PPAR-interacting ECHLP inhibitor promoting the main effect of PPAR, a substance regulating the side effect of PPAR.gamma., a PPAR-interacting AOP2 inhibitor regulating the side effect of PPAR.gamma., a PPAR-interacting FLJ1311 activator promoting the main effect of PPAR or an FLJ13111 expression accelerator which can be obtained by the above screening method. |